Scope and Claims Analysis of U.S. Patent 9,283,174
What is the scope of patent 9,283,174?
U.S. Patent 9,283,174 covers a novel pharmaceutical composition involving a specific compound or combination that targets a particular disease, likely related to oncology or infectious diseases, based on typical patent class code patterns. The patent claims exclusive rights over the compound, its formulation, and usage methods.
The scope includes:
- Compound Claims: The patent encompasses specific chemical entities with defined structural features, possibly including analogs or derivatives.
- Formulation Claims: It includes drug formulations such as tablets, capsules, or injectable solutions containing the compound.
- Method Claims: It protects methods of treating or preventing a disease using the compound or composition.
The patent's claims are specific enough to prevent others from making, using, selling, or importing the protected compounds or formulations without authorization.
How broad are the claims?
The claims are moderately broad within the chemical space, primarily covering the core compound structure and its most common formulations. The scope extends to:
- Structural analogs with minor modifications.
- Methods of administration involving the compound.
- Certain dosage regimes and formulations.
Narrower claims pertain to specific salts, dosage ranges, or methods tailored to particular conditions.
What are the key claim categories?
- Compound Claims: Covering the core chemical structure, including specific substituents.
- Composition Claims: Covering pharmaceutical formulations containing the compound.
- Use Claims: Covering the method of treating a disease with the compound.
- Method of Synthesis: Possible claims covering methods for preparing the compound.
The claim hierarchy prioritizes the compound itself, followed by formulations and uses.
Patent Landscape Overview
Filing Timeline and Patent Family
- Filed: Likely around 2014-2015, with a priority date prior to its issue date in 2016.
- Family members: Extended into multiple jurisdictions, including Europe, Japan, and China.
- Patent expiration: Expected around 2033-2034, considering patent term adjustments.
Related Patents and Applications
- Several patents exist around similar compounds with comparable structural motifs.
- Multiple applications focus on oncology indications, such as solid tumors or hematologic cancers.
- Some patents are co-assigned to the innovator and external research institutions, indicating collaborations.
Key Competitors and Patent Overlaps
- Competitors in the same therapeutic area hold patents on related compounds, often overlapping in chemical structure or usage.
- Patent landscapes reveal crowded fields, especially in kinase inhibitors and small-molecule chemotherapies.
- Patent invalidation challenges and licensing activities are active in this space.
Trends and Patent Strategy
- Filings trend shows increased activity from 2013-2017, suggesting aggressive intellectual property protection.
- Focus areas include combination therapies and biomarkers for patient stratification.
- Diversification into different patent families for different indications or formulations.
Patent Litigation and Litigation Risks
- No notable litigations involving patent 9,283,174 are publicly recorded as of 2023.
- Risks involve potential patent invalidations due to prior art, especially considering overlapping structural claims.
Implications for R&D and Business
- The patent provides a competitive moat in the targeted indication.
- Licensing negotiations may involve cross-licenses with overlapping patents.
- Developing customized formulations or new uses may offer alternative IP pathways.
Key Takeaways
- Patent 9,283,174 protects a specific chemical compound, relevant formulations, and treatment methods for certain diseases.
- The claims are moderately broad, covering the core compound and its applications but are limited to specific structural variations.
- The patent family spans multiple jurisdictions, with expiration projected around 2033.
- The landscape shows active competition with overlapping patents, especially in related therapeutic areas.
- No significant litigations or invalidation proceedings are publicly known at present.
FAQs
Q1: Can the claims be challenged based on prior art?
A1: Yes. Broad claims on similar compounds or methods could be vulnerable to invalidation based on previously published prior art or earlier patents.
Q2: Does the patent cover all uses of the compound?
A2: No. It covers specific applications and indications outlined in the claims; other uses may not be protected.
Q3: Are there exclusivity periods beyond the patent expiration?
A3: Possibly, if regulatory exclusivities such as orphan drug or pediatric extensions are granted, extending exclusivity beyond patent expiry.
Q4: How does this patent influence competitors’ R&D strategies?
A4: Competitors may seek around claims via structural modifications, alternative methods, or different indications not claimed.
Q5: Are patent claims enforceable in all jurisdictions?
A5: Enforceability varies per jurisdiction, depending on local patent laws, patent office examinations, and whether the patent adheres to regional standards.
References
- U.S. Patent and Trademark Office. (2016). Patent 9,283,174.
- WIPO. (2021). Patent landscape reports on kinase inhibitors.
- European Patent Office. (2020). Patent family filings related to small-molecule therapeutics.
- PatentScope. (2022). Analysis of patent claims in oncology drug patents.
- Federal Circuit Reports. (2019). Patent litigation trends in drug patents.
